GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Land And Improvements

CHRO (Chromocell Therapeutics) Land And Improvements : $0.00 Mil (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Land And Improvements?

Chromocell Therapeutics's land and improvements for the quarter that ended in Jun. 2024 was $0.00 Mil.


Chromocell Therapeutics Land And Improvements Historical Data

The historical data trend for Chromocell Therapeutics's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Land And Improvements Chart

Chromocell Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Land And Improvements
- - - -

Chromocell Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Chromocell Therapeutics Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Chromocell Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.

Chromocell Therapeutics Headlines

From GuruFocus

Chromocell Announces Stock Repurchase Plan

By Marketwired 08-07-2024